Treatment of acne with topical antibiotics: Lessons from clinical studies

British Journal of Dermatology

Volumn 153, Issue 2, 2005, Pages 395-403

  Simonart, T ^a   Dramaix, M ^b  

^a ERASME HOSPITAL   (Belgium)

^b School of Public Health   (Belgium)

Author keywords

Acne; Clindamycin; Erythromycin; Resistance; Topical antibiotics

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; ERYTHROMYCIN;

ACNE; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HUMAN; PRIORITY JOURNAL; PROPIONIBACTERIACEAE; SYSTEMATIC REVIEW;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 24144432147     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06614.x     Document Type: Article

References (84)

1. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196:130-4.
2. Gollnick HP, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology 2003; 206:29-36.
3. Ross JI, Snelling AM, Carnegie E et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148:467-78.
4. Esterly NB, Filrey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70:51-5.
5. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121:51-7.
6. Leyden JJ. Antibiotic resistant acne. Cutis 1976; 17:593-6.
7. Eady EA, Cove JH, Blake J et al. Recalcitrant acne vulgaris. Clinical, biochemical and microbiological investigation of patients not responding to antibiotic treatment. Br J Dermatol 1988; 118:415-23.
8. Eady EA, Jones CE, Tipper JL et al. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306:555-6.
9. Fulton JE Jr, Pablo G. Topical antibacterial therapy for acne. Study of the family of erythromycins. Arch Dermatol 1974; 110:83-6.
10. Mills OH, Kligman AM. The clinical effectiveness of topical erythromycin in acne vulgaris. Cutis 1975; 15:93-6.
11. Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58:555-7.
12. Hellgren L, Vincent J. Topical erythromycin for acne vulgaris. Dermatologica 1980; 161:409-14.
13. Leyden JJ, McGinley K, Mills OH, Kligman AM. Topical antibiotics and topical antimicrobial agents in acne therapy. Acta Derm Venereol Suppl (Stockh) 1980; 89:75-82.
14. Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne vulgaris. J Am Acad Dermatol 1980; 2:318-21.
15. Rivkin L, Rapaport M. Clinical evaluation of a new erythromycin solution for acne vulgaris. Cutis 1980; 25:552-5.
16. Dobson RL, Belknap BS. Topical erythromycin solution in acne. Results of a multiclinic trial. J Am Acad Dermatol 1980; 3:478-82.
17. Feucht CL, Allen BS, Chalker DK, Smith JG Jr. Topical erythromycin with zinc in acne. A double-blind controlled study. J Am Acad Dermatol 1980; 3:483-91.
18. Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topical erythromycin in inflammatory acne. Drug Intell Clin Pharm 1981; 15:372-6.
19. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117:551-3.
20. Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of acne vulgaris. Cutis 1982; 29 (624-5):628-32.
21. Rapaport M, Puhvel SM, Reinser MR. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis 1982; 30:122-35.
22. Burke B, Eady EA, Cunliffe WJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108:199-204.
23. Chalker DK, Shalita A, Smith JG Jr, Swann RW. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9:933-6.
24. Shahlita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison. Arch Dermatol 1984; 120:351-5.
25. Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect of Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol 1984; 11:86-9.
26. Lesher JL Jr, Chalker DK, Smith JG Jr et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985; 12:526-31.
27. Leyden JJ, Shalita AR, Saatjian GD, Sefton J. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J Am Acad Dermatol 1987; 16:822-7.
28. Swinyer LJ, Baker MD, Swinyer TA, Mills OH Jr. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 119:615-22.
29. Pochi PE, Bagatell FK, Ellis CN et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41:132-6.
30. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res 1989; 15:447-51.
31. Habbema L, Koopmans B, Menke HE et al. A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. Br J Dermatol 1989; 121:497-502.
32. Schachner L, Eaglstein W, Kittles C, Mertz P. Topical erythromycin and zinc therapy for acne. J Am Acad Dermatol 1990; 22:253-60.
33. Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22:489-95.
34. Bojar RA, Eady EA, Jones CE et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130:329-36.
35. Eady EA, Bojar RA, Jones CE et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134:107-13.
36. Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Br J Dermatol 1997; 136:235-8.
37. Lookingbill DP, Chalker DK, Lindholm JS et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37:590-5.
38. Morel P, Vienne MP, Beylot C et al. Clinical efficacy and safety of a topical combination of retinaldehyde 0.1% with erythromycin 4% in acne vulgaris. Clin Exp Dermatol 1999; 24:354-7.
39. Glass D, Boorman GC, Stables GI et al. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999; 199:242-7.
40. Leyden JJ, Hickman JG, Jarratt MT et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5:37-42.
41. Thiboutot D, Jarratt M, Rich P et al. A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clin Ther 2002; 24:773-85.
42. Draelos ZD, Tanghetti EA. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis 2002; 69:20-9.
43. Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of double strength isotrexin versus benzamycin in the topical treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2002; 13:111-17.
44. Mills O Jr, Thornsberry C, Cardin CW et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 8:260-5.
45. Gupta AK, Lynde CW, Kunynetz RA et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003; 7:31-7.
46. Poulos ET, Tedesco FJ. Acne vulgaris: double-blind trial comparing tetracycline and clindamycin. Arch Dermatol 1976; 112:974-6.
47. Stoughton RB, Resh W. Topical clindamycin in the control of acne vulgaris. Cutis 1976; 17:551-4.
48. Guin JD. Topical clindamycin: a double-blind study comparing clindamycin phosphate with clindamycin hydrochloride. Int J Dermatol 1979; 18:164-6.
49. Panzer JD, Panzer JJ. Topical clindamycin in acne: a preliminary study. Cutis 1979; 24:118-9.
50. Stoughton RB, Cornell RC, Gange RW, Walter JF. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980; 26:424-19.
51. Padilla RS, McCabe JM, Becker LE. Topical tetracycline hydrochloride vs. topical clindamycin phosphate in the treatment of acne: a comparative study. Int J Dermatol 1981; 20:445-8.
52. Guin JD. Treatment of acne vulgaris with topical clindamycin phosphate: a double-blind study. Int J Dermatol 1981; 20:286-8.
53. McKenzie MW, Beck DC, Popovich NG. Topical clindamycin formulations for the treatment of acne vulgaris. An evaluation. Arch Dermatol 1981; 117:630-4.
54. Becker LE, Bergstresser PR, Whiting DA et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol 1981; 117:482-5.
55. Gratton D, Raymond GP, Guertin-Larochelle S et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J Am Acad Dermatol 1982; 7:50-3.
56. Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983; 22:41-3.
57. Braathen LE. Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand J Infect Dis 1984; 43:71-5.
58. Tucker SB, Tausend R, Cochran R, Flannigan SA. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110:487-92.
59. Goltz RW, Coryell GM, Schnieders JR, Neidert GL. A comparison of Cleocin T 1 percent solution and Cleocin T 1 percent lotion in the treatment of acne vulgaris. Cutis 1985; 36:265-8.
60. Kuhlman DS, Callen JP. A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis 1986; 38:203-6.
61. Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987; 116:387-91.
62. Parker F. A comparison of clindamycin 1% solution versus clindamycin 1% gel in the treatment of acne vulgaris. Int J Dermatol 1987; 26:121-2.
63. Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL. A comparison of Cleocin T solution, Cleocin T gel, and placebo in the treatment of acne vulgaris. Cutis 1988; 42:245-7.
64. Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm Venereol 1990; 70:534-7.
65. Shalita AR, Smith JG, Parish LC et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 1995; 34:434-7.
66. Packman AM, Brown RH, Dunlap FE et al. Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. Int J Dermatol 1996; 35:209-11.
67. Cambazard F. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris. J Eur Acad Dermatol Venereol 1998; 11:S20-7.
68. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998; 11:227-33.
69. Richter JR, Bousema MT, De Boulle KLVM et al. Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac) in the topical control of facial acne lesions. J Dermatol Treat 1998; 9:81-90.
70. Zouboulis CC, Derumeaux L, Decroix J et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143:498-505.
71. Leyden JJ, Berger RS, Dunlap FE et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol 2001; 2:33-9.
72. Tschen EH, Katz HI, Jones TM et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 2001; 67:165-9.
73. Rizer RL, Sklar JL, Whiting D et al. Clindamycin phosphate 1% gel in acne vulgaris. Adv Ther 2001; 18:244-52.
74. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24:1117-33.
75. Weiss JW, Shavin J, Davis M. Preliminary results of a nonrandomized, multicenter, open-label study of patient satisfaction after treatment with combination benzoyl peroxide/clindamycin topical gel for mild to moderate acne. Clin Ther 2002; 24:1706-17.
76. Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003; 49:S211-17.
77. Fagundes DS, Fraser JM, Klauda HC. New therapy update. A unique combination formulation in the treatment of inflammatory acne. Cutis 2003; 72:16-19.
78. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169:259-61.
79. Unkles SE, Gemmell CG. Effect of clindamycin, erythromycin, lincomycin, and tetracycline on growth and extracellular lipase production by propionibacteria in vitro. Antimicrob Agents Chemother 1982; 21:39-43.
80. Eady EA, Gloor M, Ley den JJ. Propionebacterium acnes resistance: a worldwide problem. Dermatology 2003; 206:54-6.
81. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4:813-31.
82. Simonart T. Antibiotic-resistant acne: lessons from good sense. Br J Dermatol 2004; 150:369-70.
83. Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis 2004; 73 (Suppl. 6):6-10.
84. Simpson N. Antibiotics in acne: time for a rethink. Br J Dermatol 2001; 144:225-8.